- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Cancer
- Interventions
- Topotecan, Cisplatin, Paclitaxel
- Drug
- Lead sponsor
- John P. Fruehauf
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Orange, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 2,297
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801
- Drug · Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 2 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastroduodenal Ulcerations, Erosion
- Interventions
- PL3100, Naproxen
- Drug
- Lead sponsor
- PLx Pharma
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- Healthy
- Interventions
- MTX-463, Placebo
- Biological · Other
- Lead sponsor
- Mediar Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
- Interventions
- Daratumumab
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Phoeniz, Arizona • Loma Linda, California • Los Angeles, California + 13 more
- Conditions
- Bowel Dysfunction, Constipation
- Interventions
- Placebo, Alvimopan, Alviompan
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 119
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Avelumab, M9241, Avelumab (Once weekly), M9241 (MTD), Avelumab (Expansion cohort)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- San Diego, California • Santa Rosa, California • New Haven, Connecticut + 13 more
- Conditions
- Lymphoma
- Interventions
- rituximab, Bendamustin, bortezomib, lenalidomide
- Biological · Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 227
- States / cities
- Greenbrae, California • Salinas, California • Stanford, California + 158 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, chemotherapy, efaproxiral, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 6 more
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 2 more
- Conditions
- Cancer of Larynx
- Interventions
- Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Duvelisib
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Duarte, California • Boston, Massachusetts • Portland, Oregon
- Conditions
- Parkinson Disease
- Interventions
- autologous dopaminergic cell implantation
- Biological
- Lead sponsor
- Jeffrey S. Schweitzer, MD, PhD
- Other
- Eligibility
- 45 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- Tulisokibart, Companion Diagnostic (CDx)
- Biological · Diagnostic Test
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Liberty, Kansas • Chesterfield, Michigan + 11 more
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Amifostine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 15
- States / cities
- Decatur, Illinois • Urbana, Illinois • Wichita, Kansas + 12 more
- Conditions
- Ulcerative Colitis Acute
- Interventions
- Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended Release Oral Tablet, Intravenous Methylprednisolone, Prednisone Oral Product
- Drug
- Lead sponsor
- Berinstein, Jeffrey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Healthy Volunteer
- Interventions
- MRG-110, Placebo
- Drug
- Lead sponsor
- miRagen Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 45 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- temsirolimus, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Nivolumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Drug · Procedure
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Shreveport, Louisiana • Myrtle Beach, South Carolina
- Conditions
- PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
- Interventions
- Rituximab, Brentuximab Vedotin, Bendamustine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Rochester, Minnesota
- Conditions
- Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy
- Drug · Biological
- Lead sponsor
- Lazaros Lekakis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
- Interventions
- Allodepleted T Cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 2
- States / cities
- Houston, Texas